DRUG Watch

dc.contributor.author	Aschenbrenner, Diane S.
dc.contributor.department	Sandra R. Berman School of Nursing and Health Professions	en
dc.contributor.program	Nursing	en
dc.date.accessioned	2017-09-27T20:11:37Z
dc.date.available	2017-09-27T20:11:37Z
dc.date.issued	2017-06
dc.description.abstract	The article reports on drugs that received approval from the U.S. Food and Drug Administration. It notes on the approval given to deflazacort (Emflaza) as treatment for Duchenne muscular dystrophy, the most common type of muscular dystrophy characterized by progressive muscle deterioration and weakness starting in childhood. It cites the approval given to brodalumab (Siliq) as treatment for moderate-to-severe plaque psoriasis, an autoimmune disease that causes patches of red and flaky skin.	en
dc.description.uri	https://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=123295317&site=eds-live&scope=site	en
dc.format.extent	2 pages	en
dc.genre	journal articles	en
dc.identifier	doi:10.13016/M23J3921B
dc.identifier.citation	Aschenbrenner, D. S. (2017). Drug watch. AJN American Journal Of Nursing, 117(6), 22-23.	en
dc.identifier.issn	0002-936X
dc.identifier.uri	http://hdl.handle.net/11603/5652
dc.language.iso	en	en
dc.publisher	American Journal of Nursing	en
dc.title	DRUG Watch	en
dc.type	Text	en

Files

Now showing 1 - 1 of 1